Learn More
Invitrogen™ LRRK2 [G2019S] Recombinant Protein
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene, which codes for a multidomain protein kinase, are considered the most common genetic cause of late-onset autosomal-dominant Parkinson's disease.
Brand: Invitrogen™ A15201
Additional Details : Weight : 0.01000kg
Description
This full-length, purified and active LRRK2 G2019S mutant protein may be useful in research to better understand the most common Parkinson's disease-relevant mutant, as well as to explore the mechanisms underlying the disease.
- Increase disease relevance by interrogating a purified and active full-length LRRK2 protein
- Uncover novel compounds or hits specific to the full-length form
- Advance Parkinson 's research using the full-length protein and validated assays
Specifications
NP_940980.3 | |
288kDa | |
Store at -68 to -85°C. Aliquot at first use to avoid multiple freeze-thaws. If properly stored, this product is guaranteed for 6 months from date of purchase. Suspended in: 50 mM Tris (pH 7.5), 150 mM NaCl, 0.5 mM EDTA, 0.02% Triton™X–100, 2 mM DTT, and 50% glycerol. |
|
AURA17, DARDARIN, PARK8, RIPK7, ROCO2 | |
Human | |
Mammalian |
Kinase Assay, Target and Lead Identification and Validation, Kinase Biology, Kinase Assay, Protein Biology, Enzyme and Protein Activity Assay, Kinase Assay, Protein Assays and Analysis, Industrial and Applied Science, Pharma and Biopharma | |
100μg | |
Full Length | |
LRRK Kinase Family | |
DYKDDDDK |